|Bid||75.01 x 1400|
|Ask||75.02 x 900|
|Day's range||74.35 - 75.61|
|52-week range||61.45 - 89.74|
|Beta (5Y monthly)||0.39|
|PE ratio (TTM)||17.24|
|Earnings date||25 Oct 2023 - 30 Oct 2023|
|Forward dividend & yield||3.00 (3.99%)|
|Ex-dividend date||14 Sept 2023|
|1y target est||85.46|
Stock valuations are at historically high levels. Three Motley Fool contributors identified bargain stocks to buy in a market that's priced for perfection. Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE).
Gilead's (GILD) Veklury gets a positive CHMP opinion, recommending the use of the drug to treat people with COVID-19 with mild to severe hepatic impairment.
FOSTER CITY, Calif., September 19, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury® (remdesivir) to treat people with COVID-19 with mild to severe hepatic impairment. The European Commission (EC) will review the CHMP recommendation and, if adopted, Veklury will become the first and only authorized antiviral COVID-19 treatment that can